Pharsight

1. Onzetra Xsail patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP08736896A	2021-06-08	Beck Greener LLP	Patent maintained as amended
EP13715145A	2020-09-03	ELKINGTON AND FIFE LLP	Granted and Under Opposition
EP00906570A	2005-09-27	Direct-Haler A/S	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8047202	CURRAX	Nasal devices	Jul, 2023 (2 months ago)
US8327844	CURRAX	Nasal delivery method	Oct, 2023 (4 days from now)
US9119932	CURRAX	Nasal delivery device	Apr, 2024 (6 months from now)
US7975690	CURRAX	Nasal devices	Aug, 2025 (1 year, 10 months from now)
US8590530	CURRAX	Nasal delivery devices	Sep, 2025 (1 year, 11 months from now)
US9108015	CURRAX	Nasal delivery devices	Sep, 2025 (1 year, 11 months from now)
US11571531	CURRAX	Powder delivery devices	Feb, 2026 (2 years from now)
US10124132	CURRAX	Nasal delivery	Mar, 2027 (3 years from now)
US10398859	CURRAX	Nasal delivery devices	Dec, 2027 (4 years from now)
US8875704	CURRAX	Nasal administration	Apr, 2028 (4 years from now)
US10722667	CURRAX	Nasal administration	Dec, 2028 (5 years from now)
US10076615	CURRAX	Nasal delivery	Jul, 2029 (5 years from now)
US8550073	CURRAX	Nasal delivery	Oct, 2029 (6 years from now)
US8899229	CURRAX	Powder delivery devices	Aug, 2030 (6 years from now)
US9649456	CURRAX	Nasal administration	Oct, 2030 (7 years from now)
US8978647	CURRAX	Nasal delivery	Dec, 2030 (7 years from now)
US10478574	CURRAX	Nasal administration	Nov, 2033 (10 years from now)
US10076614	CURRAX	Nasal delivery devices	Oct, 2034 (11 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: Method of drug delivery via the nasal cavity; Acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; Acute treatment of migraine; T...

Dosage: POWDER;NASAL

Strength	Dosage	Availability
EQ 11MG BASE	POWDER;NASAL	Prescription

ONZETRA XSAIL family patents

2. Silenor patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8513299	August, 2011	Decision	Roberta L. Rogowski et al

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238620	CURRAX	Methods of using low-dose doxepin for the improvement of sleep	May, 2027 (3 years from now)
US9486437	CURRAX	Methods of using low-dose doxepin for the improvement of sleep	May, 2027 (3 years from now)
US9861607	CURRAX	Methods of using low-dose doxepin for the improvement of sleep	May, 2027 (3 years from now)
US10653662	CURRAX	Methods of using low-dose doxepin for the improvement of sleep	May, 2027 (3 years from now)
US9572814	CURRAX	Methods of improving the pharmacokinetics of doxepin	Jul, 2027 (3 years from now)
US10653660	CURRAX	Methods of improving the pharmacokinetics of doxepin	Jul, 2027 (3 years from now)
US11110074	CURRAX	Methods of improving the pharmacokinetics of doxepin	Jul, 2027 (3 years from now)
US7915307	CURRAX	Methods of improving the pharmacokinetics of doxepin	Aug, 2027 (3 years from now)
US11234954	CURRAX	Low-dose doxepin for treatment of sleep disorders in elderly patients	Jan, 2028 (4 years from now)
US9907780	CURRAX	Low-dose doxepin formulations and methods of making and using the same	Apr, 2028 (4 years from now)
US11096920	CURRAX	Low-dose doxepin formulations and methods of making and using the same	Apr, 2028 (4 years from now)
US10548871	CURRAX	Low-dose doxepin formulations and methods of making and using the same	Apr, 2028 (4 years from now)
US9107898	CURRAX	Methods of using low-dose doxepin for the improvement of sleep	May, 2028 (4 years from now)
US9532971	CURRAX	Low-dose doxepin formulations and methods of making and using the same	Jun, 2029 (5 years from now)
US8513299	CURRAX	Methods of using low-dose doxepin for the improvement of sleep	Sep, 2030 (6 years from now)

Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient

Market Authorisation Date: 17 March, 2010

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
3 mg and 6 mg	16 Sep, 2010	2	26 Jul, 2013	17 Feb, 2020	Extinguished Eligible

Strength	Dosage	Availability
EQ 3MG BASE	TABLET;ORAL	Prescription
EQ 6MG BASE	TABLET;ORAL	Prescription

SILENOR family patents

3. Treximet patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US7332183	November, 2015	Terminated-Denied	POZEN Inc.	Graybar Pharmaceuticals, LLC

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7332183	CURRAX	Multilayer dosage forms containing NSAIDs and triptans	Oct, 2025 (2 years from now)
US7332183 (Pediatric)	CURRAX	Multilayer dosage forms containing NSAIDs and triptans	Apr, 2026 (2 years from now)